N
Nathalie Dartois
Researcher at Pfizer
Publications - 23
Citations - 2440
Nathalie Dartois is an academic researcher from Pfizer. The author has contributed to research in topics: Tigecycline & Population. The author has an hindex of 16, co-authored 23 publications receiving 2177 citations.
Papers
More filters
Journal ArticleDOI
The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam
E. J. Ellis Grosse,Timothy Babinchak,Nathalie Dartois,Gilbert M. Rose,Evan Loh,cSSSI Study Groups +5 more
TL;DR: Tigecycline monotherapy is as safe and efficacious as the vancomycin-aztreonam combination in treating patients with cSSSI.
Journal ArticleDOI
The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data
TL;DR: It is demonstrated that tigecycline was efficacious and well tolerated in the treatment of patients with complicated intra-abdominal infections and microbiological modified intent-to-treat populations.
Journal ArticleDOI
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Antonio T. Freire,Vasyl Melnyk,Min Ja Kim,Oleksiy Datsenko,Oleksandr Dzyublik,Felix Glumcher,Yin Ching Chuang,Robert Maroko,Gary Dukart,C. Angel Cooper,Joan M. Korth-Bradley,Nathalie Dartois,Hassan Gandjini +12 more
TL;DR: Overall, the tigecycline regimen was noninferior to the imipenem/cilastatin regimen for the c-mITT but not the CE population; this difference appears to have been driven by results in VAP patients.
Journal ArticleDOI
Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease
TL;DR: Physicians should target individuals with COPD, asthma, heart disease or diabetes mellitus, and those who smoke, for pneumococcal vaccination at the earliest opportunity at any time of the year.
Journal ArticleDOI
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Julio A. Ramirez,Nathalie Dartois,Hassan Gandjini,Jean Li Yan,Joan M. Korth-Bradley,Paul C. McGovern +5 more
TL;DR: The hypothesis that a higher area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) may be necessary to achieve clinical cure in patients with hospital-acquired pneumonia is supported.